ライフサイエンスコーパス: CAR-T cell therapy

1 with SC alone without treatment crossover to CAR T cell therapy.

2 cytotoxic T cell-mediated killing, improving CAR T cell therapy.

3 eatly enhanced the potency of DLL3-targeting CAR T cell therapy.

4 RS, representing a safe and potent anti-CD19 CAR T cell therapy.

5 guidelines on the care of children receiving CAR T cell therapy.

6 ich limit the potential lifelong benefits of CAR T cell therapy.

7 cilitate safer application of effective CD19 CAR T-cell therapy.

8 ncing CRS and other adverse events following CAR T-cell therapy.

9 inued for 7.5 months after the initiation of CAR T-cell therapy.

10 s with haematological malignancies receiving CAR T-cell therapy.

11 les in the complicated multi-step process of CAR T-cell therapy.

12 ge B-cell lymphoma who developed ICANS after CAR T-cell therapy.

13 fold in patients with B-ALL in CR after CD19 CAR T-cell therapy.

14 -up of patients in remission after anti-CD19 CAR T-cell therapy.

15 f genetically modified T cells, most notably CAR T-cell therapy.

16 nitiated, combining GSI with concurrent BCMA CAR T-cell therapy.

17 must unfold to enable tumour eradication by CAR T-cell therapy.

18 improved antitumor efficacy of BCMA-targeted CAR T-cell therapy.

19 nhibitors (GSIs) could augment BCMA-targeted CAR T-cell therapy.

20 ibody engineering, antibody humanization and CAR-T cell therapy.

21 e development of CRS and neurotoxicity after CAR-T cell therapy.

22 ns and facilitates escape from CD19-directed CAR-T cell therapy.

23 ed and refractory MLL-B-ALL who receive CD19 CAR-T-cell therapy.

24 roved efficacy compared to monospecific BCMA-CAR-T-cell therapy.

25 r after receiving chimeric antigen receptor (CAR) T cell therapy.

26 ologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.

27 apy, particularly chimeric antigen receptor (CAR) T-cell therapy.

28 d by conventional chimeric antigen receptor (CAR) T-cell therapy.

29 nical trials and inform the design of future CAR T cell therapies.

30 ective strategy for improving the potency of CAR T cell therapies.

31 and/or reduce the toxicities associated with CAR T cell therapies.

32 re consistent with those reported with other CAR T-cell therapies.

33 at lead to disease recurrence following many CAR T-cell therapies.

34 the first metabolic modification to enhance CAR-T cell therapies.

35 have demonstrated the curative potential of CAR T cell therapy, a substantial and well-established l

36 argeted bispecific adapters greatly augments CAR T-cell therapies against heterogeneous tumors, highl

37 ing T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.

38 second-generation chimeric antigen receptor (CAR) T cell therapy against ROBO1, a cell surface recept

39 e the benefits of chimeric antigen receptor (CAR)-T cell therapies against lymphoid malignancies, res

40 atment approach to prevent antigen escape in CAR-T cell therapy against MM, and the vertically integr

41 l with the CAR gene can confer resistance to CAR T-cell therapy and lead to treatment failure.

42 in CAR T cells might improve the efficacy of CAR T-cell therapy and other emerging cellular immunothe

43 -five (85%) of 53 patients who received CD19 CAR T-cell therapy and were evaluable for response achie

44 nt sources of T cells for optimal allogeneic CAR-T cell therapy and describe the different technologi

45 demonstrated by several therapeutics such as CAR-T cell therapy and stem cell transplantation that ha

46 n recipients of chimeric antigen receptor-T (CAR-T) cell therapies and other immunocompromised popula

47 Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL in t

48 ) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory lar

49 ologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/

50 ologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/

51 ous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory lar

52 ous CD19-directed chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory man

53 However, improved CAR T cell therapies are still needed.

54 t strategies of side-effects associated with CAR T-cell therapy are of high relevance.

55 Chimeric antigen receptor (CAR) T cell therapies are approved as a third-line or la

56 f solid tumors to chimeric antigen receptor (CAR) T cell therapy are often minimal.

57 CD19-specific CAR-T cell therapies are the gold standard of adoptive c

58 r chimeric antigen receptor-modified T-cell (CAR-T-cell) therapy are limited.

59 data illustrate the potential use of SLAMF7-CAR T-cell therapy as an effective treatment against mul

60 ) Subgroup and the MD Anderson Cancer Center CAR T Cell Therapy-Associated Toxicity (CARTOX) Program

61 ) received corticosteroids for management of CAR T-cell therapy-associated toxicities.

62 ymphodepletion chemotherapy followed by CD19 CAR T-cell therapy at our institution.

63 ho presented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital

64 CAR T cell therapy (axicabtagene ciloleucel and tisagenl

65 d of enormous preclinical efforts to develop CAR T-cell therapy beyond B-cell malignancies.

66 e, highlighting the feasibility of extending CAR-T cell therapies beyond canonical B-cell malignancie

67 After CAR T cell therapy, both patients experienced rapid clin

68 factors determining the utility of anti-CD19 CAR T-cell therapy, but long-term follow-up of patients

69 w, we highlight recent strategies to improve CAR-T cell therapy by engineering (1) the CAR protein, (

70 The high response rates after anti-CD19 CAR T-cell therapy can be used to guide the use of thera

71 Anti-CD19 chimeric antigen receptor (CAR) T cell therapies can cause severe cytokine-release

72 Chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions of rel

73 Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cyto

74 Chimeric antigen receptor (CAR) T-cell therapy can lead to dramatic clinical respon

75 Chimeric antigen receptor-T (CAR-T) cell therapies can eliminate relapsed and refract

76 Chimeric antigen receptor (CAR) T-cell therapy (CAR-T) has revolutionized the treat

77 antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is u

78 A next-generation CAR T-cell therapy containing additional potency gene ed

79 Among children who successfully receive CAR T-cell therapy, CR and overall survival are equitabl

80 As haematopoietic reconstitution after CAR T-cell therapy differs from chemotherapy-associated

81 ll malignancies, multiple clinical trials of CAR T cell therapy directed to CD19 have led to the appr

82 Chimeric antigen receptor (CAR) T cell therapy effectively treats human cancer, but

83 5 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-h

84 stantial impact in broadening application of CAR-T cell therapy, especially for solid tumors.

85 Our CAR T-cell therapy exhibited cytotoxicity against both l

86 As the use of CAR T-cell therapy expands to include a wider patient po

87 unexpected organ damage and deaths following CAR T-cell therapy first highlighted the possible danger

88 atment and may improve the overall safety of CAR T-cell therapies for cancer patients.

89 ve B-cell lymphoma showed the feasibility of CAR T-cell therapy for cancer in this excluded group.

90 CAR T-cell therapy for glioblastoma is promising; howeve

91 ion strategies to augment the feasibility of CAR T-cell therapy for patients with AML.

92 Our data support the safety of CD19-specific CAR T-cell therapy for R/R B-ALL.

93 Chimeric antigen receptor (CAR) T cell therapies for DIPG have demonstrated clinica

94 Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpasse

95 inical success of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies represents a

96 ettings, adoptive chimeric antigen receptor (CAR) T cell therapy for cancer requires further improvem

97 Chimeric antigen receptor (CAR) T cell therapy for solid tumors encounters challeng

98 Chimeric antigen receptor (CAR) T cell therapy for solid tumours is challenging bec

99 in the success of chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors is

100 ent failure after chimeric antigen receptor (CAR) T-cell therapy for acute lymphoblastic leukemia.

101 el (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory large B-c

102 Advancements in chimeric antigen receptor (CAR) T-cell therapy for treating diffuse large B-cell ly

103 ion to developing chimeric antigen receptor (CAR)-T cell therapies for solid tumors is identifying su

104 Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to h

105 However, the development of CAR-T cell therapies for solid tumors is hampered by the

106 As experience with CAR T-cell therapy grows, distinct and infrequent neurol

107 CAR T cell therapy has become a standard-of-care treatme

108 CAR T cell therapy has revolutionized the treatment of a

109 CAR T cell therapy has shown great promise for the treat

110 CAR T-cell therapy has emerged as a transformative treat

111 Cellular immunotherapy such as CAR T-cell therapy has entered clinical routine in hemat

112 applicability against cancers where standard CAR T-cell therapy has failed.

113 Chimeric antigen receptor T-cell (CAR T-cell) therapy has been shown to be clinically effe

114 Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in h

115 Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in t

116 Chimeric antigen receptor (CAR) T cell therapy has been successful for hematologica

117 Chimeric antigen receptor (CAR) T cell therapy has been successful in clinical tria

118 Chimeric antigen receptor (CAR) T cell therapy has created a paradigm shift in the

119 Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treat

120 Chimeric antigen receptor (CAR) T cell therapy has led to a paradigm shift in cance

121 Chimeric antigen receptor (CAR) T cell therapy has led to impressive clinical respo

122 Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented responses i

123 Chimeric antigen receptor (CAR) T cell therapy has opened new possibilities for pat

124 Chimeric antigen receptor (CAR) T cell therapy has proved remarkably successful for

125 Chimeric antigen receptor (CAR) T cell therapy has resulted in positive effects on

126 Chimeric antigen receptor (CAR) T cell therapy has revolutionized cancer treatment

127 Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of

128 Chimeric Ag receptor (CAR) T cell therapy has shown astonishing potency in tre

129 Chimeric antigen receptor (CAR) T cell therapy has shown considerable promise for h

130 BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses

131 Chimeric antigen receptor (CAR) T cell therapy has shown extraordinary results in t

132 Chimeric antigen receptor (CAR) T cell therapy has shown impressive clinical respon

133 Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy for the m

134 Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic mal

135 Chimeric antigen receptor (CAR) T cell therapy has shown remarkable success in trea

136 Chimeric antigen receptor (CAR) T cell therapy has transformed cancer treatment but

137 Chimeric antigen receptor (CAR) T cell therapy has yielded unprecedented outcomes i

138 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become a breakthrough treatment

139 As a result, chimeric antigen receptor (CAR) T-cell therapy has become a new and highly effectiv

140 CD19 chimeric antigen receptor (CAR) T-cell therapy has become the standard of care in r

141 Chimeric Antigen Receptor (CAR) T-cell therapy has demonstrated efficacy in childre

142 nti-CD19-directed chimeric antigen receptor (CAR) T-cell therapy has had a resounding effect on the t

143 Chimeric antigen receptor (CAR) T-cell therapy has had considerable success in the

144 Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor r

145 Chimeric antigen receptor (CAR) T-cell therapy has proven effective in relapsed and

146 Chimeric antigen receptor (CAR) T-cell therapy has proven to be a promising treatme

147 Chimeric antigen receptor (CAR) T-cell therapy has redefined the therapeutic landsc

148 CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of

149 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable activity in pat

150 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical effica

151 d chimeric antigen receptor-engineered (CD19 CAR) T-cell therapy has shown significant efficacy for r

152 Chimeric antigen receptor (CAR) T-cell therapy has significantly advanced the treat

153 Autologous chimeric antigen receptor (CAR) T-cell therapy has transformed the management of B-

154 Chimeric antigen receptor (CAR)-T cell therapy has had unprecedented impact in the

155 ous "living drug" chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer medicine.

156 Although chimeric antigen receptor (CAR)-T cell therapy has shown promise in targeting PC, i

157 Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical effica

158 Chimeric antigen receptor T (CAR-T) cell therapy has produced impressive results in c

159 The rapidity of commercial utilization of CAR-T-cell therapy has created a largely unexplored gap

160 CAR T cell therapies have had remarkable impact, curing

161 ors associated with durable remissions after CAR T-cell therapy have not been fully elucidated.

162 Although chimeric antigen receptor (CAR) T cell therapies have demonstrated considerable suc

163 Chimeric antigen receptor (CAR) T cell therapies have demonstrated durable remissio

164 Chimeric antigen receptor (CAR) T cell therapies have demonstrated immense clinical

165 Although chimeric antigen receptor (CAR) T cell therapies have demonstrated promising clinic

166 Chimeric antigen receptor (CAR) T cell therapies have poor efficacy in solid tumors

167 Chimeric Antigen Receptor (CAR) T cell therapies have received increasing attention

168 Chimeric antigen receptor (CAR) T cell therapies have shown clinical success in tre

169 Chimeric antigen receptor (CAR) T cell therapies have successfully treated hematolo

170 Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B ce

171 Chimeric antigen receptor (CAR) T-cell therapies have demonstrated transformative e

172 n (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have generated responses in patien

173 but to autoimmune diseases for which ex vivo CAR-T cell therapies have shown strong promise, such as

174 Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the treatment of he

175 As the field continues to evolve, CAR-T cell therapies hold significant potential for revo

176 Chimeric antigen receptor (CAR) T cell therapy holds significant promise for the tr

177 this review, we discuss the obstacles facing CAR T cell therapy, how these relate to our current unde

178 the bone marrow by flow cytometry after CD19 CAR-T-cell therapy; however, within 1 month of CAR-T-cel

179 matopoietic cell transplantation (HCT) after CAR T-cell therapy (HR, 0.39) were associated with bette

180 te-of-the-art clinical data on CD19-directed CAR T cell therapies in B cell hematologic malignancies,

181 mplications for the development of effective CAR T cell therapies in cancer patients.

182 fficacy and/or prevent the widespread use of CAR T cell therapies in these patients as well as in tho

183 A small but in-depth study of allogeneic CAR T cell therapy in patients with high-risk neuroblast

184 ese devices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect agai

185 Challenges relating to CAR T-cell therapies in paediatric malignancies and how

186 2019, post-approval evaluation of anti-CD19 CAR T-cell therapy in people with HIV and aggressive B-c

187 In this international study of CAR T-cell therapy in relapsed or refractory diffuse lar

188 ment rendered murine melanoma susceptible to CAR T-cell therapy in vivo with enhanced infiltration of

189 cal assessment of chimeric antigen receptor (CAR) T cell therapies in this setting.

190 he application of chimeric antigen receptor (CAR) T cell therapy in cancers.

191 he successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials involving p

192 idated target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM).

193 ion CD19-directed chimeric antigen receptor (CAR) T-cell therapy in pediatric and young adult (AYA) r

194 active target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acu

195 ciated target for chimeric antigen receptor (CAR)-T cell therapy in multiple myeloma (MM).

196 i-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic

197 We also discuss the outlook for CAR T-cell therapies, including managing toxicities and

198 17, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adu

199 e, as well as the unaddressed integration of CAR T-cell therapy into conventional anticancer treatmen

200 CAR-T cell therapy involves harvesting a patient's T cel

201 CD19-CAR T cell therapy is feasible, safe, and mediates poten

202 CAR T cell therapy is highly amenable to molecular engin

203 Although CAR T cell therapy is increasingly used to treat relapse

204 ever, in solid tumors, the full potential of CAR T cell therapy is limited by the availability of cel

205 CAR T-cell therapy is an FDA-approved therapy that has i

206 However, CAR T-cell therapy is associated with multiple adverse e

207 CAR T-cell therapy is associated with reversible acute t

208 CAR T-cell therapy is different from previous anti-myelo

209 mor microenvironment on clinical outcomes of CAR T-cell therapy is emerging from preclinical and clin

210 As CAR T-cell therapy is extending towards other diseases a

211 A major bottleneck for the success of CAR T-cell therapy is our inability to monitor the accum

212 The main adverse effect of CAR T-cell therapy is potentially life-threatening cytok

213 CAR T-cell therapy is usually given to patients with hae

214 CAR T-cell therapy is well tolerated and effective in pa

215 jor limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these c

216 Chimeric antigen receptor (CAR) T cell therapy is a 'living drug' in which the T ce

217 Chimeric antigen receptor (CAR) T cell therapy is a highly effective treatment for

218 Chimeric antigen receptor (CAR) T cell therapy is a medical breakthrough in the tre

219 Chimeric Antigen Receptor (CAR) T cell therapy is a pivotal treatment for hematolog

220 Chimeric antigen receptor (CAR) T cell therapy is an option in R/R FL after two or

221 Chimeric antigen receptor (CAR) T cell therapy is associated with a unique spectrum

222 nical response to chimeric antigen receptor (CAR) T cell therapy is correlated with CAR T cell persis

223 Chimeric antigen receptor (CAR) T cell therapy is effective in lymphoid malignancie

224 Chimeric antigen receptor (CAR) T cell therapy is effective in treating B cell mali

225 Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunother

226 Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients

227 Chimeric antigen receptor (CAR) T cell therapy is used in treating human hematologi

228 Chimeric Antigen Receptor (CAR) T-cell therapy is a highly effective treatment for

229 Chimeric antigen receptor (CAR) T-cell therapy is an emerging immunotherapy against

230 ologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of rel

231 Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is highly promising but requires rob

232 Chimeric antigen receptor (CAR) T-cell therapy is one of the most remarkable advanc

233 CAR-T cell therapy is an effective cancer therapy for mu

234 CAR-T cell therapy is effective for hematologic malignan

235 Chimeric antigen receptor T (CAR-T) cell therapy is a new pillar in cancer therapeuti

236 efficacy, the general application of current CAR-T--cell therapy is limited by serious treatment-rela

237 dly progressive disease and where autologous CAR-T-cell therapy is unavailable.

238 CAR-T-cell therapies may induce toxicities including cyt

239 X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, may have benefit in patients with r

240 ove the safety of chimeric antigen receptor (CAR) T cell therapies, micrometre-sized ICEp were inject

241 is tLNP platform holds the potential to make CAR T cell therapies more accessible and applicable acro

242 patients and provides the rationale to apply CAR T-cell therapy more broadly in ALL therapy.

243 rategy could enable the wider application of CAR-T cell therapies not just to blood cancers but to au

244 dicate that FRbeta is a promising target for CAR T-cell therapy of AML, which may be augmented by com

245 Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to

246 942 patients received CAR T-cell therapy, of whom 258 (27%) required admission

247 CAR T cell therapies often lack specificity, leading to

248 mples from chimeric antigen receptor T cell (CAR-T cell) therapy patients without washing away excess

249 le preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenograf

250 ge rare neurotoxicity presentations, such as CAR T-cell therapy-related cerebral edema, severe motor

251 fusion and severe toxicities associated with CAR T cell therapy remain major issues.

252 ned disruption of inhibitory checkpoints and CAR T cell therapy remains incompletely explored.

253 CAR T cell therapy remains ineffective in solid tumors,

254 ess and toxicity grades, ICU mortality after CAR T-cell therapy remains low.

255 n (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies represent a promising treatment st

256 Although chimeric antigen receptor (CAR) T cell therapy represents a transformative immunoth

257 CAR T-cell therapy research and development has built on

258 nderstanding of the underlying mechanisms of CAR T-cell therapy resistance in solid tumors is necessa

259 discuss the short-term strategies to improve CAR T-cell therapy responses, particularly for solid tum

260 ement with immunosuppressive agents has made CAR T cell therapy safer and more feasible than it was w

261 ologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with re

262 Although CAR T cell therapy shows promise for paediatric rheumati

263 Chimeric antigen receptor (CAR) T cell therapy stands as a transformative advanceme

264 or microenvironment for factors that predict CAR T-cell therapy success, and iii) evaluating side eff

265 er treatment, the chimeric antigen receptor (CAR) T cell therapy suffers from complications such as c

266 Although clinically approved CAR-T cell therapies target B cell lineage antigens, sol

267 Chimeric antigen receptor (CAR) T cell therapies targeting B cell maturation antige

268 Chimeric antigen receptor (CAR) T cell therapies targeting CD19 and CD22 have been

269 homa treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease

270 Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high efficacy

271 Chimeric antigen receptor (CAR) T cell therapies targeting single antigens have per

272 Chimeric antigen receptor (CAR) T cell therapy targeting B cell maturation antigen

273 Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable cl

274 Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendo

275 Chimeric antigen receptor (CAR) T-cell therapy targeting solid tumors has stagnated

276 CAR-T cell therapies targeting DLL3 have recently emerge

277 eloma (MM) that is resistant to conventional CAR-T cell therapy targeting B-cell maturation antigen (

278 n autologous CD19 chimeric antigen receptor (CAR) T-cell therapy that is approved for the treatment o

279 st that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antig

280 The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and elimina

281 Two CAR T-cell therapies, tisagenlecleucel and axicabtagene

282 The ability of CAR T cell therapy to eliminate tumor was moderately imp

283 Despite the enthusiasm, application of CAR T-cell therapy to solid tumours has had little succe

284 in order to adapt chimeric antigen receptor (CAR) T-cell therapies to treat heterogeneous solid tumor

285 findings reveal a fundamental limitation to CAR-T cell therapy to eradicate HIV.

286 ciated with favorable effectiveness, but the CAR T-cell therapy use in older patients was low, especi

287 CAR T-cell therapy was associated with favorable effecti

288 CAR T-cell therapy was used in third line and beyond in

289 s the efficacy of chimeric antigen receptor (CAR) T cell therapies, which redirect T cells to solid t

290 Understanding the limitations of CAR T cell therapy will be critical to realizing the ful

291 antaged households and neighborhoods receive CAR T-cell therapy with a higher disease burden.

292 efractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durab

293 CD19 CAR T-cell therapy with concurrent ibrutinib was well to

294 particularly for solid tumours, by combining CAR T-cell therapy with radiotherapy through the use of

295 at can preclude durable remissions following CAR T cell therapy, with a primary focus on the resistan

296 aluable patients were 38% and 50% after CD19 CAR T-cell therapy, with and without concurrent ibrutini

297 ng applied to monitor both tumour burden and CAR T cell therapy within a systemically induced mouse t

298 Chimeric antigen receptor (CAR) T cell therapy works by mechanisms distinct from th

299 esized that a combination of alpha-4-1BB and CAR T-cell therapy would result in improved antitumor re

300 CAR T-cell therapy yielded high response rates.